Immunokines shape the tumor microenvironment dictating the course of tumor dormancy and progression. Our recent study has identified CXCL7 as a key promoter of breast cancer advancement via FAK-MMP13 axis. In this study, targeting CXCL7 with neutralizing antibodies led to a significant decrease in xenograft growth and recurrence. Suppression of CXCL7 not only reduced tumor growth but also inhibited metastatic spread and the infiltration of CD11b-CD11c+ plasmacytoid dendritic cells (pDCs), a factor linked to early relapse and poor survival in ovarian cancer, within murine xenograft tumors. Administering CXCL7monoclonal antibodies post-surgery in mice effectively prevented tumor recurrence in an immunocompetent model. Serum CXCL7levels emerged as a reflective marker of tumor progression. This study highlights the pivotal role of CXCL7 in reshaping the immune landscape within the tumor microenvironment, thus influencing tumor progression. Combining CXCL7 immunotherapy with conventional treatments holds promise for combating breast cancer.
